<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03607396</url>
  </required_header>
  <id_info>
    <org_study_id>AFP-AZT-2017-01</org_study_id>
    <nct_id>NCT03607396</nct_id>
  </id_info>
  <brief_title>Study for Evaluating the Real Use of Inhaled Aztreonam Lysine in Patients With Cystic Fibrosis</brief_title>
  <acronym>REALIZA-FQ</acronym>
  <official_title>Study for Evaluating the Real Use of Inhaled Aztreonam Lysine in Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this observational trial is to evaluate the pulmonary function in cystic fibrosis
      patients that have been treated with inhaled aztreonam lysine comparing the previous 12
      months before the treatment and the forward 12 months after initiating the treatment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1</measure>
    <time_frame>12 months</time_frame>
    <description>Forced expiratory volume in one second (FEV1) measured during pulmonary function test.</description>
  </primary_outcome>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Cystic Fibrosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Cystic fibrosis patients colonized by Pseudomonas aeruginosa
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients above 6 years old that have been treated with Aztreonam Lysine (AZLI) at any
             time within 12 months before starting the treatment

          -  Diagnosis of Cystic Fibrosis confirmed

          -  Chronic infection by Pseudomonas aeruginosa

          -  Patients can be treated with any inhaled antibiotic before or after AZLI treatment

          -  Patients have to have the following FEV1 measures: 12 months before starting AZLI; at
             AZLI initiation; 12 months after starting AZLI

          -  For lung transplant patiens, only data before the transplant will be collected.

        Exclusion Criteria:

          -  Non applicable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olga SanchezMaroto</last_name>
    <phone>934893000</phone>
    <email>olga.sanchez-maroto@vhir.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurora Fernandez</last_name>
      <phone>934893000</phone>
      <email>aufernan@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Aurora Fernandez</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Gartner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Alv√°rez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emilio Monte</last_name>
    </contact>
    <investigator>
      <last_name>Emilio Monte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Luna, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carmen Luna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 23, 2018</study_first_submitted>
  <study_first_submitted_qc>July 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>July 23, 2018</last_update_submitted>
  <last_update_submitted_qc>July 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

